报价延迟最少15分钟:2026/05/14 14:06 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
171.44 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
8.05/14.38
|
|
企业价值
42.88B
|
| 资产负债 |
|
每股账面净值
37.27
|
| 现金流量 |
|
现金流量率
0.09
|
| 损益表 |
|
收益
16.31B
|
|
每股收益
89.01
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its reserach and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry,and it serves biopharmaceutical firms, providers, payers, and policymakers. |
